rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

David P. Bonita

Director

Company insider

Files Form 4 as: Director, ImageneBio; Director and 10% owner, Prelude Therapeutics; Director and 10% owner, Third Harmonic Bio; Director, Repare Therapeutics; Director and 10% owner, Acutus Medical; Director and 10% owner, Tricida; Director and 10% owner, Enliven Therapeutics; Director, Si-Bone.

Every Form 4 they filed

In numbers

Trades disclosed
242
Buys
26
Sells
23
Bought
$180.4M
Sold
$139.2M
Companies
11
Companies where not an officer
11
First trade
20 May 2013
Last trade
16 Jun 2026
Last filed
18 Jun 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
IMA ImageneBioDirector · Biotechnology · last 16 Jun 20266 buys · 0 sells
PRLD Prelude TherapeuticsDirector, 10% owner · Biotechnology · last 9 Jun 20263 buys · 0 sells
Third Harmonic BioDirector, 10% owner · last 11 Aug 20251 buy · 0 sells
Repare TherapeuticsDirector · last 17 Jun 20241 buy · 15 sells
Acutus MedicalDirector, 10% owner · last 15 Jun 20232 buys · 0 sells
TricidaDirector, 10% owner · last 25 Nov 20222 buys · 4 sells
ELVN Enliven TherapeuticsDirector, 10% owner · Biotechnology · last 2 Jun 20223 buys · 0 sells
SIBN Si-BoneDirector · Medical Devices · last 19 Oct 20181 buy · 0 sells
Loxo OncologyDirector, 10% owner · last 8 Dec 20171 buy · 4 sells
ViewRayDirector, 10% owner · last 15 Nov 20172 buys · 0 sells
Ambit BiosciencesDirector, 10% owner · last 15 May 20144 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
01Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
16 Jun 2026filed 18 Jun 2026IMA ImageneBiooption or derivative · BiotechnologySEC FORM 4 Code A—15,600 at $0.00filing
16 Jun 2026filed 18 Jun 2026IMA ImageneBiooption or derivative · BiotechnologySEC FORM 4 Code A—15,600 at $0.00filing
9 Jun 2026filed 10 Jun 2026PRLD Prelude Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—38,000 at $0.00filing
9 Jun 2026filed 10 Jun 2026PRLD Prelude Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—38,000 at $0.00filing
21 Apr 2026filed 23 Apr 2026PRLD Prelude TherapeuticsBiotechnologySEC FORM 4 Bought$7.5M1,689,189 at $4.44filing
21 Apr 2026filed 23 Apr 2026PRLD Prelude TherapeuticsBiotechnologySEC FORM 4 Bought$5.0M1,126,126 at $4.44filing
21 Apr 2026filed 23 Apr 2026PRLD Prelude TherapeuticsBiotechnologySEC FORM 4 Bought$7.5M1,689,189 at $4.44filing
21 Apr 2026filed 23 Apr 2026PRLD Prelude TherapeuticsBiotechnologySEC FORM 4 Bought$5.0M1,126,126 at $4.44filing
14 Apr 2026filed 16 Apr 2026IMA ImageneBiooption or derivative · BiotechnologySEC FORM 4 Code P—336,603filing
14 Apr 2026filed 16 Apr 2026IMA ImageneBiooption or derivative · BiotechnologySEC FORM 4 Code P—384,689filing
14 Apr 2026filed 16 Apr 2026IMA ImageneBiooption or derivative · BiotechnologySEC FORM 4 Code P—336,603filing
14 Apr 2026filed 16 Apr 2026IMA ImageneBiooption or derivative · BiotechnologySEC FORM 4 Code P—384,689filing
11 Aug 2025filed 14 Aug 2025Third Harmonic Biooption or derivativeSEC FORM 4 Code J—43,584 at $0.00filing
11 Aug 2025filed 14 Aug 2025Third Harmonic BioSEC FORM 4 Code J—5,779,071filing
25 Jul 2025filed 30 Jul 2025IMA ImageneBiooption or derivative · BiotechnologySEC FORM 4 Code M—17,520 at $0.00filing
25 Jul 2025filed 30 Jul 2025IMA ImageneBioBiotechnologySEC FORM 4 Code M—379filing
25 Jul 2025filed 30 Jul 2025IMA ImageneBioBiotechnologySEC FORM 4 Bought$2.5M83,611 at $29.90filing
12 Jun 2025filed 13 Jun 2025PRLD Prelude Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—38,000 at $0.00filing
17 Jun 2024filed 20 Jun 2024Repare Therapeuticsoption or derivativeSEC FORM 4 Code A—27,200 at $0.00filing
14 Jun 2024filed 18 Jun 2024PRLD Prelude Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—23,500 at $0.00filing

News

Reviewing Arbutus Biopharma (NASDAQ:ABUS) & Prelude Therapeutics (NASDAQ:PRLD)PRLD · tickerreport.com · 17 Oct 2026

0 headlines in the last 90 days name David P. Bonita; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.

Sectors

Health Care13
Not placed36

Buys in green, sells in red, by the company’s sector.

Related people

Kristin YaremaChief Executive Officer · Chief Executive Officer at ImageneBio, filing Form 4 there in the last year
Yanina Grant-HuertaChief Financial Officer · Chief Financial Officer at ImageneBio, filing Form 4 there in the last year
Robert B. LallyPrincipal Accounting Officer · Principal Accounting Officer at ImageneBio, filing Form 4 there in the last year
Joseph P. SlatteryDirector · Director at ImageneBio, filing Form 4 there in the last year
Jonathan Jian WangDirector · Director at ImageneBio, filing Form 4 there in the last year
Laura FrancisChief Executive Officer · Also traded SIBN in the last 90 days
Anshul MaheshwariChief Op & Financial Officer · Also traded SIBN in the last 90 days
Michael A. PisetskySVP, Ops & Adm/Chief Legal Ofr · Also traded SIBN in the last 90 days